Eldian Biomed is building strong third-party validation through competitive Swiss innovation programs. In 2025, we advanced to Stage II of Venture Kick (link: https://www.venturekick.ch/index.cfm?page=135403&profil_id=66333&backpage=135354), securing a CHF 50’000 convertible loan to accelerate development of our lead asset CloudLi-1.
We also reached the top 20 of the Swiss Innovation Challenge 2025, finishing 11th out of 100 startups, and were selected among the top 6 finalists of the Ypsomed Innovation Award. We are reinvesting this non-dilutive funding and recognition into the preclinical and product development of CloudLi-1, our disease-modifying micro-cushion therapy for osteoarthritis.